Mouse Anti-Tick-Borne Encephalitis Virus NS1(EF10)
$406.10 – $1,725.93 excl. VAT
Mouse anti-Tick-Borne Encephalitis Virus antibody (clone EF10), purified by Protein G chromatography, recognizes the NS1 protein from Tick-Borne Encephalitis Virus (TBEV). The antibody does not cross react with other Flavivirus NS1 proteins.
MOUSE ANTI-TICK-BORNE ENCEPHALITIS VIRUS NS1 (EF10)
Mouse anti-Tick-Borne Encephalitis Virus antibody (clone EF10), purified by Protein G chromatography, recognizes the NS1 protein from Tick-Borne Encephalitis Virus (TBEV).
MOUSE ANTI-TICK-BORNE ENCEPHALITIS VIRUS NS1 (EF10)
- Monoclonal Antibody IgG1 Kappa
- Created with TBEV NS1 (The Native Antigen Company TBEV-NS1) as an immunogen
- Greater than 85% purity
- Presented as liquid, in PBS pH7.4
- No cross reactivity observed with Powasssan NS1, JEV NS1, West Nile NS1, Usutu NS1 and DENV NS1-4
BACKGROUND
Tick-borne encephalitis virus (TBEV) belongs to the genus Flavivirus, of the family Flaviviridae. The virus is primarily transmitted through the bite of infected hard ticks, of the family Ixodidae. Small rodents are the primary hosts for TBEV with humans acting as accidental hosts. The virus can also be transmitted to humans through unpasteurized milk in areas where TBEV is prevalent (CDC)
TBEV is a neurotrophic virus that causes tick-born encephalitis (TBE) in humans, affecting the central nervous system (CNS). TBE is endemic in many parts of Europe, China, Mongolia and the Russian Federation and is the most common tick-born CNS infection in these. Three subtypes of TBEV have been recognised that cause tick-borne encephalitis, which are European, Far-Eastern and Siberian.
TBEV infection is asymptomatic in most cases with some individuals presenting with influenza-like symptoms. In symptomatic cases, TBEV infection typically presents as meningitis, encephalitis or meningoencephalitis. A high percentage of acute TBE cases may also develop post-encephalitic syndrome with long-lasting neuropsychiatric symptoms or neurological dysfunction (Bogovic, P).
Diagnosis of TBE infection is primarily based on clinical presentation and serological testing for TBEV specific IgM and IgG antibodies in the patient’s serum and cerebrospinal fluid. There is no anti-viral treatment for TBEV. However, several effective vaccines for TBEV are currently available which are based on European and Far-Eastern strains of the virus (WHO)
REFERENCES
- Centers for Disease Control and Prevention: Tick-borne encephalitis (TBE)
- Bogovic P, Strle F. 2015. Tick-borne encephalitis: A review of epidemiology, clinical characteristics, and management. World J Clin Cases. May 16;3(5):430-41
- World Health Organization: Tick-borne Encephalitis vaccine